Qingxiang Guan

Dr. Qingxiang Guan


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
YLYuran Liu
Yuran Liu
CSCheng Sun
Cheng Sun
GZGuangyuan Zhang
Guangyuan Zhang
JWJi Wu
Ji Wu
LHLong Huang
Long Huang
QGQingxiang Guan
Qingxiang Guan

1 December 2021 in Phytomedicine
Verified
Journal Article
Closed access
SYShangmin Yu
Shangmin Yu
SLShan Liu
Shan Liu
NWNing Wang
Ning Wang
DYDi Yu
Di Yu
MQMeng Qin
Meng Qin
QGQingxiang Guan
Qingxiang Guan

1 December 2020 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
GZGuangyuan Zhang
Guangyuan Zhang
LHLong Huang
Long Huang
JWJi Wu
Ji Wu
YLYuran Liu
Yuran Liu
ZZZilu Zhang
Zilu Zhang
QGQingxiang Guan
Qingxiang Guan

2 December 2016 in Molecules
Verified
Journal Article
Open access
PDF file
QGQingxiang Guan
Qingxiang Guan
DSDandan Sun
Dandan Sun
GZGuangyuan Zhang
Guangyuan Zhang
CSCheng Sun
Cheng Sun
MWMiao Wang
Miao Wang
WYWei Yang
Wei Yang
Poorly soluble drugs have low bioavailability after oral administration, thereby hindering effective drug delivery. A novel drug-delivery system of docetaxel (DTX)-based stearic acid (SA)-modified Bletilla striata polysaccharides (BSPs) copolymers was successfully developed. Particle size, zeta potential, encapsulation efficiency (EE), and loading capacity (LC) were determined. The DTX release percentage in vitro was determined using high performance liquid chromatography (HPLC). The hemolysis and in vitro anticancer activity were studied. Cellular uptake and apoptotic rate were measured using flow cytometry assay. Particle size, zeta potential, EE and LC were 125.30 ± 1.89 nm, −26.92 ± 0.18 mV, 86.6% ± 0.17%, and 14.8% ± 0.13%, respectively. The anticancer activities of DTX-SA-BSPs copolymer micelles against HepG2, HeLa, SW480, and MCF-7 (83.7% ± 1.0%, 54.5% ± 4.2%, 48.5% ± 4.2%, and 59.8% ± 1.4%, respectively) were superior to that of docetaxel injection (39.2% ± 1.1%, 44.5% ± 5.3%, 38.5% ± 5.4%, and 49.8% ± 2.9%, respectively) at 0.5 μg/mL drug concentration. The DTX release percentage of DTX-SA-BSPs copolymer micelles and docetaxel injection were 66.93% ± 1.79% and 97.06% ± 1.56% in two days, respectively. Cellular uptake of DTX-FITC-SA-BSPs copolymer micelles in cells had a time-dependent relation. Apoptotic rate of DTX-SA-BSPs copolymer micelles and docetaxel injection were 73.48% and 69.64%, respectively. The SA-BSPs copolymer showed good hemocompatibility. Therefore, SA-BSPs copolymer can be used as a carrier for delivering hydrophobic drugs.

5 September 2018 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JQJin Qiao
Jin Qiao
DJDanyang Ji
Danyang Ji
SSShilin Sun
Shilin Sun
GZGuangyuan Zhang
Guangyuan Zhang
XLXin Liu
Xin Liu
QGQingxiang Guan
Qingxiang Guan
We developed self-microemulsifying drug-delivery systems (SMEDDS), including bile salts, to improve the oral bioavailability of pueraria flavones (PFs). The physical properties of the SMEDDS using Cremophor RH 40, and bile salts as mixed surfactants at weight ratios of 10:0–0:10 were determined. The particle sizes of PFs-SMEDDSNR containing sodium taurocholate (NaTC) and Cremophor RH 40, and PFs-SMEDDSR containing Cremophor RH 40 were measured upon dilution with deionized water and other aqueous media. Dilution volume presented no remarkable effects on particle size, whereas dilution media slightly influenced particle size. PFs-SMEDDSNR and PFs-SMEDDSR provided similar release rates in pH-1.2 hydrochloride solution. However, the release rate of PFs-SMEDDSNR was faster than that of PFs-SMEDDSR in pH-6.8 phosphate buffer containing 20 mM NaTC and 500 U/mL porcine pancreas lipase. The pharmacokinetics and bioavailability were measured in rats. The oral bioavailability of PFs-SMEDDSNR was 2.57- and 2.28-fold that of a suspension of PFs (PFs-suspension) before and after the blockade of the lymphatic transport route by cycloheximide, respectively. These results suggested PFs-SMEDDSNR could significantly improve the oral relative absorption of PFs via the lymphatic uptake pathway. SMEDDS containing NaTC may provide an effective approach for enhancing the oral bioavailability of PFs.

30 July 2023 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SYShangmin Yu
Shangmin Yu
XWXinying Wang
Xinying Wang
LLLinlin Lv
Linlin Lv
TLTongyan Liu
Tongyan Liu
QGQingxiang Guan
Qingxiang Guan